anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
In the Canadian Coronary Atherosclerosis Intervention Trial (CCAIT), the effect of therapy with lovastatin on coronary atherosclerosis was assessed by coronary angiography in hyperlipidemic patients. In the randomized, double-blind, controlled clinical trial, patients were treated with conventional measures (usually diet and 325 mg of aspirin every other day) and either lovastatin 20-80 mg daily or placebo. Angiograms were evaluated at baseline and at two years by computerized quantitative coronary angiography (QCA). Lovastatin significantly slowed the progression of lesions as measured by the mean change per-patient in minimum lumen diameter (the primary endpoint) and percent diameter stenosis, and decreased the proportions of patients categorized with disease progression (33% vs. 50%) and with new lesions (16% vs. 32%).

In a similarly designed trial, the Monitored Atherosclerosis Regression Study (MARS), patients were treated with diet and either lovastatin 80 mg daily or placebo. No statistically significant difference between lovastatin and placebo was seen for the primary endpoint (mean change per patient in percent diameter stenosis of all lesions), or for most secondary QCA endpoints. Visual assessment by angiographers who formed a consensus opinion of overall angiographic change (Global Change Score) was also a secondary endpoint. By this endpoint, significant slowing of disease was seen, with regression in 23% of patients treated with lovastatin compared to 11% of placebo patients.

In the Familial Atherosclerosis Treatment Study (FATS), either lovastatin or niacin in combination with a bile acid sequestrant for 2.5 years in hyperlipidemic subjects significantly reduced the frequency of progression and increased the frequency of regression of coronary atherosclerotic lesions by QCA compared to diet and, in some cases, low-dose resin.

The effect of lovastatin on the progression of atherosclerosis in the coronary arteries has been corroborated by similar findings in another vasculature. In the Asymptomatic Carotid Artery Progression Study (ACAPS), the effect of therapy with lovastatin on carotid atherosclerosis was assessed by B-mode ultrasonography in hyperlipidemic patients with early carotid lesions and without known coronary heart disease at baseline. In this double-blind, controlled clinical trial, 919 patients were randomized in a 2 x 2 factorial design to placebo, lovastatin 10-40 mg daily and/or warfarin. Ultrasonograms of the carotid walls were used to determine the change per patient from baseline to three years in mean maximum intimal-medial thickness (IMT) of 12 measured segments. There was a significant regression of carotid lesions in patients receiving lovastatin alone compared to those receiving placebo alone (p=0.001). The predictive value of changes in IMT for stroke has not yet been established. In the lovastatin group there was a significant reduction in the number of patients with major cardiovascular events relative to the placebo group (5 vs.14) and a significant reduction in all-cause mortality (1 vs. 8).
PURPOSE:To obtain an agent for the prevention and treatment of diseases caused by the increase in lipid peroxide or the generation of various free radicals accompanying the generation of thromboxane A2 inducing various diseases by using an activated vitamin D as an active component. CONSTITUTION:The objective agent for the prevention and treatment of diseases caused by the formation of lipid peroxide or thromboxane A2 is produced by using an activated vitamin D (especially preferably 1alpha-hydroxyvitamin D3, 1alpha, 24(R)-dihydroxyvitamin D3, 1alpha, 25-dihydroxyvitamin D3, etc.) as an active component. The diseases caused by the formation of lipid peroxide are e.g. autoimmune diseases, chronic pulmonary emphysema, respiratory distress syndrome of adult, shock, disseminated intravascular coagulation syndrome, gastric mucous disorder, acute pancreatitis, Crohn's disease, ulcerative colitis, ischemic enteritis, ischemic cardiopathy, cerebrovascular disorder and Parkinson's disease and the diseases caused by the generation of thromboxane A2 are e.g. ischemic cardiopathy, cerebrovascular disorder, bronchial asthma, shock and renal diseases. The agent is effective for the prevention and treatment of the above diseases.
In humans and animal models, temporal lobe epilepsy (TLE) is associated with reorganization of hippocampal neuronal networks, gliosis, neuroinflammation, and loss of integrity of the blood-brain barrier (BBB). More than 30% of epilepsies remain intractable, and characterization of the molecular mechanisms involved in BBB dysfunction is essential to the identification of new therapeutic strategies. In this work, we induced status epilepticus in rats through injection of the proconvulsant drug pilocarpine, which leads to TLE. Using RT-qPCR, double immunohistochemistry, and confocal imaging, we studied the regulation of reactive glia and vascular markers at different time points of epileptogenesis (latent phase-3, 7, and 14 days; chronic phase-1 and 3 months). In the hippocampus, increased expression of mRNA encoding the glial proteins GFAP and Iba1 confirmed neuroinflammatory status. We report for the first time the concomitant induction of the specific proteins CD31, PDGFRβ, and ColIV-which peak at the same time points as inflammation-in the endothelial cells, pericytes, and basement membrane of the BBB. The altered expression of these proteins occurs early in TLE, during the latent phase, suggesting that they could be associated with the early rupture and pathogenicity of the BBB that will contribute to the chronic phase of epilepsy.
BACKGROUND: Psoriasis is an inflammatory skin disease that occurs repeatedly over time. The natural product of sesquiterpene lactones, Parthenolide (Par), is isolated from Tanacetum parthenium L. (feverfew) which has significant effects on anti-inflammatory. The therapeutic effect of the medication itself is crucial, but different routes of administration of the same drug can also produce different effects.
PURPOSE: The aim of our research sought to investigate the ameliorating effects of Par in psoriasis-like skin inflammation and its related mechanism of action.
RESULTS: In the IMQ-induced model, intragastric administration of Par reduced the Psoriasis Area and Severity Index (PASI) score, improved skin erythema, scaling, and other symptoms. And Par decreased the expression of Ki67, keratin14, keratin16 and keratin17, and increased the expression of keratin1. Par could reduce IL-36 protein expressions, meanwhile the expression of Il1b, Cxcl1 and Cxcl2 mRNA were also decreased. Par regulated the expression levels of F4/80, MPO and NE. However, skin transdermal administration of Par was more effective. Similarly, Par attenuated IL-36γ, IL-1β and caspase-1 activated by Poly(I:C) in in vitro and ex vivo. In addition, Par also reduced NE, PR3, and Cathepsin G levels in explant skin tissues.
CONCLUSION: Par ameliorated psoriasis-like skin inflammation in both in vivo and in vitro, especially after treatment with transdermal drug delivery, possibly by inhibiting neutrophil extracellular traps and thus by interfering IL-36 signaling pathway. It indicated that Par provides a new research strategy for the treatment of psoriasis-like skin inflammation and is expected to be a promising drug.
Routine Option B+ national guidelines including HIV-1 plasmatic viral load testing will be adhered to. Visits will take place at 6-8 weeks, 6 and 12 months post-partum to collect samples from the mother for the analysis of viral load results at 12 months. In addition, at 6-8 weeks, 6 and 12 months post-partum, POC tests will be done for the diagnosis of HIV-1 in their infants (by HIV-1 DNA PCR) and results will be shared within 2 hours. Children infected with HIV-1 will be referred to the National Programme for confirmed diagnosis and immediate ART.
This is a Phase IV multicenter, open-label study and is being implemented in order to assess diagnostic image quality of MDCTA in subjects undergoing computed tomography angiography (CTA) of the thoraco-abdominal aorta, and the carotid, pulmonary and peripheral arteries with IOMERON. The hypothesis is that IOMERON used at a high concentration will provide good diagnostic image quality. The Investigators will also function as readers and evaluate the images on-site. Efficacy analysis will be based on the on-site evaluations.

Imaging conditions will be representative of those used in routine clinical practice. The study will be conducted at approximately 10-20 sites in China. Each site may enroll approximately 40 subjects in this study. Approximately 400 subjects will be enrolled in order to obtain 360 evaluable subjects who undergo elective MDCTA of the thoraco-abdominal aorta, or carotid, pulmonary or peripheral arteries.
Mometasone furoate will be available in the form of Nasonex Nasal Spray. It has a dose of 50 mcg/dose mometasone furoate per spray, registration no: MAL20001010AZ, distributed by: Merck Sharp \& Dohme (Malaysia) Sdn. Bhd.
ABSTRACT                  METHOD FOR ENHANCING HEALING OF CORNEAL ENDOTHELIAL WOUNDS           Method using a non-steroidal antiinflammatory compound, such as indomethacin and/or a growth factor that causes a change in sell function when bound to a specific cell surface receptor, such as epidermal growth factor (EGF), to enhance healing and restore function of the corneal endothelium. The compositions can be administered alone, in combination, or in sequence, before or after injury, for example, in an irrigation solution or in combination with a nutritive solution for storage of a cornea prior to transplant.           Examples of useful growth factors include, in addition to EGF and EGF-like compounds, fragments of EGF containing the receptor binding region, and EGF modified to improve stability, increase half-life, or enhance permeation into the eye. Example of other non-steroidal antiinflammatories include aspirin, ibuprofen, and suprofen. The composition can be applied topically to the eye or delivered in a controlled fashion by means of a material such as a polymeric implant, gel, or liposomes.           The effective dosage is that amount which promotes closure of corneal endothelial tissue and restores function, i.e., restores permeability, including both barrier function and pumping function.
BACKGROUND: Microalgae like Phaeodactylum tricornutum (PT) contain the carotenoid, fucoxanthin, which has been purported to promote fat loss, lower blood lipids, and improve glucose management. This study examined whether dietary supplementation with microalgae extracts from PT containing 4.4 mg/d of fucoxanthin affects changes in body composition or health markers in overweight women during an exercise and diet intervention.
MATERIALS AND METHODS: A total of 37 females (28.6 ± 7.9 years, 80.2 ± 14.9 kg, 29.6 ± 3.8 kg/m², 41.4 ± 4.2% fat) fasted for 12 h, donated a fasting blood sample, completed health and mood state inventories, and undertook body composition, health, and exercise assessments. In a counterbalanced, randomized, and double-blind manner, participants ingested a placebo (PL), or microalgae extract of Phaeodactylum tricornutum standardized to 4.4 mg of fucoxanthin (FX) for 12 weeks while participating in a supervised exercise program that included resistance-training and walking (3 days/week) with encouragement to accumulate 10,000 steps/day on remaining days of the week. The diet intervention involved reducing energy intake by about -300 kcal/d (i.e., ≈1400-1600 kcals/d, 55% carbohydrate, 30% fat, 15% protein) to promote a -500 kcal/d energy deficit with exercise. Follow-up testing was performed at 6 and 12 weeks. A general linear model (GLM) with repeated measures statistical analysis was used to analyze group responses and changes from baseline with 95% confidence intervals.
RESULTS: Dietary supplementation with microalgae extract from PT containing fucoxanthin for 12 weeks did not promote additional weight loss or fat loss in overweight but otherwise healthy females initiating an exercise and diet intervention designed to promote modest weight loss. However, fucoxanthin supplementation preserved bone mass, increased bone density, and saw greater improvements in walking steps/day, resting heart rate, aerobic capacity, blood lipid profiles, adherence to diet goals, functional activity tolerance, and measures of quality of life. Consequently, there appears to be some benefit to supplementing microalgae extract from PT containing fucoxanthin during a diet and exercise program. Registered clinical trial #NCT04761406.
Accidental overdose may lead to hemorrhagic complications. In the event of hemorrhagic complications, initiate appropriate clinical support, discontinue treatment with dabigatran etexilate, and investigate the source of bleeding. A specific reversal agent (idarucizumab) is available for adult patients.   
  
Dabigatran is primarily eliminated by the kidneys with a low plasma protein binding of approximately 35%. Hemodialysis can remove dabigatran; however, data supporting this approach are limited. Using a high-flux dialyzer, blood flow rate of 200 mL/min, and dialysate flow rate of 700 mL/min, approximately 49% of total dabigatran can be cleared from plasma over 4 hours. At the same dialysate flow rate, approximately 57% can be cleared using a dialyzer blood flow rate of 300 mL/min, with no appreciable increase in clearance observed at higher blood flow rates. Upon cessation of hemodialysis, a redistribution effect of approximately 7% to 15% is seen. The effect of dialysis on dabigatran’s plasma concentration would be expected to vary based on patient specific characteristics. Measurement of aPTT or ECT may help guide therapy [see Warnings and Precautions (5.2) and Clinical Pharmacology (12.2)].
The invention relates to a urinary system kidney tonifying and stone discharging Chinese medicine preparation. The urinary system lithiasis is a common disease and a frequently-occurring disease of a urinary system and is called urolithiasis in Chinese medicine. The urolithiasis patient is affected by Qi weakness, yang damage, kidney deficiency, dampness and heat, Qi stagnation and blood stasis. Accordingly, the kidney deficiency and Qi and blood stasis are main pathogenesis of kidney stone with hydronephrosis; and the kidney and Qi tonifying and diuresis stranguria treatment are important methods for treating kidney stone in Chinese medicine. The Chinese medicine preparation disclosed by the invention comprises the following components in parts by weight: 30 parts of desmodium, 15 parts of sunflower, 30 parts of talc, 12 parts of akebiaquinata, 15 parts of asiatic plantain, 12 parts of lygodium japonicum, 12 parts of endothelium corneum gigeriae galli, 15 parts of dianthus superbus, 6 parts of liquorice, 30 parts of astragalus mongholicus and 15 parts of rheum officinale. In addition, 2-8 parts of honey can be also added into the prescription. The urinary system kidney tonifying and stone discharging Chinese medicine preparation prescription consults Chinese medical records, selects pure Chinese medicines and can effectively treat urinary system lithiasis by clinical treatment application observation and verification.
A folk prescription for treating livestock pleuropneumonia is discloses. According to the folk prescription, a proper amount of cowpea is selected for treating livestock pleuropneumonia. If livestock catch a cold and choke continuously, cowpea can be used for feeding. According to the feeding method, cowpea is better uncooked. Big livestock are fed twice a day, once in the morning and once in the evening, 0.5-1 kg for each time. Small livestock are fed with reduced dosage. In practice, the invention concludes that ''cowpeas are better than tonic in treating damaged lung caused by continuous choke''.
<P>PROBLEM TO BE SOLVED: To proliferate merozoites of immortalized mammalian cells in vitro.  <P>SOLUTION: A method for continuously culturing obligate intracellular Protozoa, Sporozoea class, in a developmental assexual reproduction period is provided to solve the problem. The method comprises following processes: a process for providing a cell culture system containing immortalized host cells suitable for proliferating Sporozoea sp.; a process for bringing the host cells into contact with the Sporozoea sp. in an infection step under effective conditions relating to infection of the host cells; and a process for bringing proliferation of the merozoites to the host cells (wherein, the host cells are able to take the Protozoa by phagocytosis).  <P>COPYRIGHT: (C)2010,JPO&INPIT
Arm-crank exercise group will be performed twice a week for 12 weeks. In the first weeks of training, each session will consist of 15 bouts, two active minutes and two minutes of passive interval, consisting of 60 minutes of session (30 minutes of active exercise). After the first three weeks of training, the exercise time will progressively increase by one minute every 3 weeks and the recovery period will be decreased, completing, at the end, a maximum volume of 10 bouts of five minutes of exercise and one minute of passive interval. The intensity of the exercise will be determined by the load equivalent to the range of 13 - 15 of The Borg Rating of Perceived Exertion, considered as somewhat hard to hard.
The surgical procedure will be conducted following standard procedures for tooth exodontia and ridge preservation. The selected individual sites will be subjected to the standard of care extraction protocol and then randomized to receive treatment with a type I bovine Achilles tendon collagen with bioactive resorbable calcium apatite crystals (CCAC)(Osteogen) ridge augmentation procedures. Intra-oral photographs will be made at the same optic focal distance using a ruler which will be used to evaluate areas where the membrane is still exposed and not epithelized. At 4-6 weeks and again at 20 weeks postoperatively, each study subject will return for implant placement in the ridge preservation area.
Inguinal hernia repair is one of the most performed procedures in children, but aspects of care remain controversial. The aim of this review was to provide a critical appraisal of recently published guidelines on the management of inguinal hernias in children, by the American Academy of Pediatrics (2023) and the European Pediatric Surgeons' Association Evidence and Guideline Committee (2022). This was achieved by delineating areas of controversy and reviewing the most relevant recent literature on these topics. Currently available moderate-to-low quality evidence recommends postponing hernia repair in premature infants until after discharge, to reduce the risk of respiratory difficulties and recurrence. Laparoscopic repair provides similar outcomes to open but may shorten operative time in bilateral cases. No clear recommendation can be made for contralateral exploration, therefore should be evaluated case by case. In preterm infants, consideration of regional anaesthesia may reduce post-operative apnoea and pain, with no difference in neurodevelopment outcomes.
The present invention discloses a formula for skin-care, where in the formula comprises green tea extract, ginseng extract, grape seed extract, ointment base and liquid base. The formula comprise 25% to 55% green tea extract, 25 to 45% ginseng extract and 20% to 30% grape seed extract. Green tea extract, ginseng extract and grape seed extract and ointment base formed ointment skin care composition, and green tea extract, ginseng extract and grape seed extract and liquid-based formed skin care composition. The invention also disclosed a method for preparing the skin care composition. In addition, the invention also discloses the use of the skin care composition. The skin care compositions can improve the skin aging symptoms, including inhibition SA[beta]-galactosidase, the skin aging symptoms caused by free radicals or ultraviolet rays, wrinkles and loss of collagen, their preparation and their use.
FIELD: medicine, pharmaceutics. ^ SUBSTANCE: invention relates to pharmaceutical industry and medicine. Claimed is application of N-carbamoyl-4-(n-methoxyphenyl)-2-pyrrolidone of structural formula as means possessing antidepressive, anxiolytic and nootropic action. This low-toxic compound (LD50 2263.88 mg/kg) possesses high antidepressive, anxiolytic and nootropic activity, affect of which is not accompanied by hypnosedative phenomena, or reduction of mental and physical work ability. ^ EFFECT: demonstrated is antidepressive and anxiolytic action of compound already in its single application, which makes the medication different from most known antidepressants, requiring at least one-week long intake to develop their effect. ^ 7 tbl
The prevalence of social isolation and loneliness among older adults is a public health problem. It is reported that 25 % of community-dwelling older adults 65 and older are socially isolated while 43 % of older adults 60 and older feel lonely (Cudge et al., 2020). Research has shown that social isolation and loneliness are associated with cardiovascular disease, stroke, depression, dementia, and mortality (Holjlerda, 2016). Loneliness, in particular, has been identified as a potential predictor of mild cognitive impairment (Bundy, et al., 2021; Sutin et al., 2018; Dahlberg, 2021). As a result of the prevalence data, gerontologists and researchers have cited the need for developing, implementing and testing innovative interventions to address this problem. Reminiscence is one example of a cost-effective intervention shown to decrease loneliness and improve mental health and wellness.

STORII is a telephone reminiscence program designed to provide a service that automatically calls older adults three times a week asking them meaningful questions about their lives. The participants have the opportunity to select curated prompts that enable them to record their life stories through the phone. The participants can choose to share them online with their families. Through formative evaluation of the program, the STORII team has noted that their participants to be highly satisfied and highly engaged. As a result of these informal data, it was decided that a more in-depth investigation should be undertaken. Therefore, the purpose of this study is to examine the impact of the STORII program on reminiscence functions and mental health outcomes in community-dwelling older adults.

Participants will be invited to join a telephone reminiscence program designed to provide a service that automatically calls older adults three times a week asking them meaningful questions about their lives. Examples of the questions are "What is the best meal you have ever tasted?", "What is one of your proudest moments?", "What is your earliest memory?". Participants can share as much or as little as they would like. They have up to 10 minutes to record the answers and can end the call at any time by hanging up. There will be no operator on the line that can hear or respond. The participants can choose to share their stories online with their families.

All outcome measures will be assessed at baseline (T0), 6-week post-test (T1), and at 12-week follow-up (T2). Participants will complete assessments via phone, by trained research assistants using four questionnaires. Assessments will be completed by research assistants who are not aware of participants' allocation.
Family-based mindfulness intervention is a parallel-group intervention containing one parent program and one child program. The parent mindfulness program lasts for 6 weeks, one session per week, and each session lasts for 1.5 hours. The child mindfulness program lasts for 8 weeks, one session per week, and each session lasts for 1 hour. In the fourth and sixth sessions of the parent program, 30-minute joint practice of parents and children is incorporated. All sessions are implemented by qualified instructors.
Mind in Labor: Working with Pain in Childbirth (MIL) is a 16-hour mindfulness-based childbirth education course. It is an abbreviated weekend workshop form of the 9-week Mindfulness-Based Childbirth and Parenting (MBCP) education program, which is a tailored form of Mindfulness-Based Stress Reduction.